English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Helena Marzo-Ortega, Pierluigi Meroni, Eva GalindezAgirregoikoa, Frank Behrens, Andrew J. Bradley, Soyi Liu Leage, Miriam Garcia, Christophe Sapin, Ji Chen Ho, Arnaud Constantin and Stephen Hall NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UNITED KINGDOM, Istituto Auxologico Italiano, University of Milan, Milan, ITALY, Servicio de Reumatologı́a, University Hospital of Basurto, Bilbao, SPAIN, Division of Rheumatology and IME Fraunhofer Project Group Translational Medicine & Pharmacology, Johann Wolfgang Goethe-University, Frankfurt am Main, GERMANY, Lilly International, Eli Lilly and Company, Indianapolis, IN, Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, TAIWAN, Department of Rheumatology, Hospital Pierre-Paul Riquet, Tolouse, FRANCE, and Department of Medicine, Monash University, Victoria, AUSTRALIA

O03 Efficacy and safety of ixekizumab at week 24 in biologic experienced patients with active psoriatic arthritis summary results